Viral detection testing is recommended for COVID-19 diagnosis. Testing decisions should be based on local epidemiology, clinical signs and symptoms, and the course of the illness. 

​

Our SARS‑CoV‑2 Assay is a real-time PCR-based in vitro diagnostic test that detects SARS‑CoV‑2 nucleic acid in nasopharyngeal swab (NPS) and anterior nasal swab samples.

​

Test Results 

​

A negative result indicates that SARS-CoV-2 RNA was not present in the specimen above the limit of detection. However, a negative result does not exclude the possibility of COVID-19 and should not be used as the sole basis for treatment or patient management. The possibility of a false-negative result should be considered if the patient’s recent exposures or clinical presentation suggests that COVID-19 is likely. Retesting may be advisable in symptomatic individuals with an intermediate or high clinical suspicion of COVID-19 and should be considered based on clinical judgment in combination with the recommendation of public health authorities.

​

Methodology: Reverse Transcription Polymerase chain reaction (RT-PCR)

​

Expected Turnaround Time: 24 hours 

(Turnaround time is defined as the usual number of days from the date of pickup of a specimen for testing to when the result is released to the ordering provider. In some cases, additional time should be allowed for additional confirmatory or additional reflex tests.)

​

Specimen: Nasopharyngeal swab and Anterior Nasal Swab (ANS) 

​

Causes for Rejection: Improper collection; inadequate specimen; improper labeling; specimen leaked in transit; quantity not sufficient for analysis; name discrepancies; specimen exceeding storage requirements; incorrect nasopharyngeal swab in viral transport media.

Respiratory Pathogens Panel

Our Respiratory panel provides qualitative detection and identification of viral and bacterial nucleic acids in nasopharyngeal swabs that most commonly cause respiratory infections. The system utilizes reverse transcription (RT), polymerase chain reaction (PCR), and microarray hybridization to detect gene sequences of the following organism types and subtypes.

​

Test Results: 

​

Negative results in the presence of a respiratory illness do not preclude respiratory infection and may be due to infection with pathogens that are not detected by this test or lower respiratory tract infection that is not detected by an NPS specimen.

​

Test Includes:  

​

                    Viruses: Adenovirus; Bordetella pertussis; SARS-CoV-2; human metapneumovirus; influenza A; influenza A subtype H1; influenza A subtype                                    H3; influenza B; parainfluenza virus 1; parainfluenza virus 2; parainfluenza virus 3; parainfluenza virus 4; Respiratory Syncytial Virus A;                                                      Respiratory Syncytial Virus B and Rhinovirus 

                    Bacteria: Bordetella parapertussis/bronchiseptica Bordetella holmesii Bordetella pertussis

​

Methodology: RT-Polymerase chain reaction (RT-PCR)

​

Expected Turnaround Time: 24 hours 

(Turnaround time is defined as the usual number of days from the date of pickup of a specimen for testing to when the result is released to the ordering provider. In some cases, additional time should be allowed for additional confirmatory or additional reflex tests.)

​

Specimen: Nasopharyngeal swab and Anterior Nasal Swab (ANS) 

​

Causes for Rejection: Improper collection; inadequate specimen; improper labeling; specimen leaked in transit; quantity not sufficient for analysis; name discrepancies; specimen exceeding storage requirements; incorrect nasopharyngeal swab in viral transport media.

​